Dan Forche serves as President and CEO of PreludeDx, a leader in precision diagnostics for early-stage breast cancer. Dan’s 25 plus years of operational and commercial diagnostic experience includes positions with medical device, lab services, and molecular testing companies, including Abbott Laboratories, CombiMatrix Corporation, Agendia Inc., and various others. Before joining PreludeDx, he was President of Pathnostics, a full-service cancer diagnostics company providing clinical and molecular pathology testing services throughout the U.S. Dan received a B.S.B.A. in marketing from Central Michigan University College of Business. Dan’s previous speaking engagements include presentations at the G2 Lab Institute, The College of American Pathology Annual Meeting, Adaptive Business Leaders Round Table and numerous investor conferences. Additionally, in 2022, he was listed as one of the top 30 CEOs by Silicon Review and received the 2020 Innovator of the year from ABL.